出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年9月
Metabolism Assays Market – Global Forecast to 2028
代謝アッセイ市場 : 製品（機器、アッセイキット）、テクノロジー（比色分析、蛍光分析、分光分析）、用途［診断（糖尿病、肥満）、研究］、エンドユーザー（病院、診断研究所）、地域別 – 2028年までの世界予測
Metabolism Assays Market by Product (Instruments, Assays Kits), Technology (Colorimetry, Fluorimetry, Spectrometry), Application (Diagnostics (Diabetes, Obesity), Research), End User (Hospitals, Diagnostic Laboratories), & Region – Global Forecast to 2028
| ページ数 | 188 |
| 図表数 | 164 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth of this market is majorly driven by the promotion of metabolic research and funding by the government, the growing use of metabolism assays in fitness and sports industry, and an increase in the awareness of early diagnosis. However, issues related high cost of metabolism assays restrain the growth of this market.
“The assay kits & reagents segment accounted for the highest market share in the metabolism assays market, by product, during the forecast period.”
Based on the product segment, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share is due to their integration with technologies, such as wearable devices and wide use in diagnostics as it is the major application
“Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes accounted for the highest CAGR during the forecast period.”
Based on end users, the metabolism assays market is segmented into hospitals, diagnostic laboratories, and pharmaceutical & biotechnology companies and CROs & academic research institutes. The pharmaceutical & biotechnology companies and CROs & academic research institutes segment dominated the metabolism assays market in 2022. The diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period. The large share of this segment can be attributed to increasing R&D investments by pharmaceutical & biotechnology companies on metabolic research.
“The North America segment accounted for the highest market share in the metabolism assays market, by region, during the forecast period.”
Based on the region, the global metabolism assays market is categorized into North America, Europe, Asia Pacific, and Rest of the World. During the forecast period North America is expected to witness a high market share. The presence of robust pharma & biotech industries who are involved in drug discover, toxicity testing & development and the increasing target disease population are supporting the growth of the metabolism assays market. However, Asia Pacific is expected to register highest CAGR during the forecast period.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Company Type: Tier 1 (30%), Tier 2 (48%), and Tier 3 (22%)
- By Designation: C-level (28%), Director-level (33%), and Others (39%)
- By Region: North America (21%), Asia-Pacific (34%), Europe (30%), and RoW (15%)
Prominent companies include Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), Kaneka Eurogentec S.A. (Belgium), Sartorius AG (Germany), Promega Corporation (US), Elabscience Biotechnology Inc. (US), RayBiotech Life Inc. (US), BMG LABTECH (Germany), BIOTREND ChemiKalien GmbH (Germany), 3H Biomedical AB (Sweden), BioAssay Systems (US), EMELCA Bioscience (Netherlands), Creative Bioarray (US), Tempo Bioscience, Inc (US), Ncardia (Netherlands), NOVOCIB (France), Eton Bioscience Inc. (US), Cayman Chemical Company (US), Enzo Lifesciences, Inc. (US), and Abnova Corporation (Taiwan).
Research Coverage
This research report categorizes the metabolism assays market by product, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the metabolism assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product & service launches, mergers and acquisitions, and recent developments associated with the metabolism assays market. Competitive analysis of upcoming startups in the metabolism assays market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall metabolism assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the metabolism assays market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the metabolism assays market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the metabolism assays market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the metabolism assays market
• Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US), among others in the metabolism assays market strategies.
Table of Contents
1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
TABLE 1 INCLUSIONS AND EXCLUSIONS 24
1.3 STUDY SCOPE 25
1.3.1 YEARS CONSIDERED 26
1.4 CURRENCY CONSIDERED 26
1.5 STAKEHOLDERS 26
1.6 LIMITATIONS 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 1 METABOLISM ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY 28
2.1.1 SECONDARY DATA 29
2.1.1.1 Secondary sources 30
2.1.2 PRIMARY DATA 30
TABLE 2 KEY DATA FROM PRIMARY SOURCES 31
FIGURE 2 KEY INDUSTRY INSIGHTS 32
2.1.2.1 Breakdown of primary interviews 33
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 33
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 33
2.2 MARKET SIZE ESTIMATION 34
FIGURE 5 BOTTOM-UP APPROACH: REVENUE-BASED APPROACH 34
2.2.1 GROWTH FORECAST 35
2.2.2 CAGR PROJECTIONS 35
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 35
2.2.3 TOP-DOWN APPROACH 36
FIGURE 7 METABOLISM ASSAYS MARKET: TOP-DOWN APPROACH 36
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 37
FIGURE 8 DATA TRIANGULATION METHODOLOGY 37
2.4 MARKET SHARE/RANKING ANALYSIS 38
2.5 STUDY ASSUMPTIONS 38
2.6 RISK ASSESSMENT 38
2.7 IMPACT OF RECESSION 39
3 EXECUTIVE SUMMARY 40
FIGURE 9 METABOLISM ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION) 40
FIGURE 10 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 41
FIGURE 11 METABOLISM ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION) 42
FIGURE 12 METABOLISM ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 43
FIGURE 13 REGIONAL SNAPSHOT OF METABOLISM ASSAYS MARKET 44
4 PREMIUM INSIGHTS 45
4.1 METABOLISM ASSAYS MARKET OVERVIEW 45
FIGURE 14 INCREASED PREVALENCE OF OBESITY AND DIABETES TO DRIVE METABOLISM ASSAYS MARKET 45
4.2 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT (2022) 46
FIGURE 15 ASSAY KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE IN 2022 46
4.3 REGIONAL GROWTH OPPORTUNITIES IN METABOLISM ASSAYS MARKET 47
FIGURE 16 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 47
4.4 METABOLISM ASSAYS MARKET: REGIONAL MIX 48
FIGURE 17 ASIA PACIFIC MARKET TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD 48
4.5 METABOLISM ASSAYS MARKET: DEVELOPED VS. EMERGING ECONOMIES 48
FIGURE 18 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN METABOLISM ASSAYS MARKET 49
5.2.1 DRIVERS 50
5.2.1.1 Increasing funding and investments in metabolic research 50
5.2.1.2 Drug discovery and development 50
5.2.1.3 Rise in prevalence of chronic diseases 50
5.2.1.4 Increased use of metabolism assays in fitness and sports 51
5.2.1.5 Growing demand for personalized medicines 51
5.2.2 RESTRAINTS 51
5.2.2.1 High cost of metabolism assay analyzers 51
5.2.2.2 Presence of alternative methods and techniques 52
5.2.3 OPPORTUNITIES 52
5.2.3.1 Integration with wearable devices 52
5.2.3.2 Growing life science research in emerging economies 52
5.2.4 CHALLENGES 53
5.2.4.1 Complexity of assay development 53
5.3 PRICING ANALYSIS 54
TABLE 3 AVERAGE SELLING PRICE OF PRODUCT, BY KEY PLAYERS 54
5.4 PATENT ANALYSIS 56
FIGURE 20 PATENT ANALYSIS FOR METABOLISM ASSAYS (JANUARY 2013–DECEMBER 2022) 56
5.4.1 LIST OF KEY PATENTS 57
5.5 VALUE CHAIN ANALYSIS 57
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASES 58
5.6 SUPPLY CHAIN ANALYSIS 59
FIGURE 22 METABOLISM ASSAYS MARKET: SUPPLY CHAIN ANALYSIS 59
5.7 ECOSYSTEM ANALYSIS 60
FIGURE 23 METABOLISM ASSAYS MARKET: ECOSYSTEM ANALYSIS 60
5.7.1 METABOLISM ASSAYS MARKET: ROLE IN ECOSYSTEM 61
FIGURE 24 KEY PLAYERS IN METABOLISM ASSAYS MARKET 61
5.8 PORTER’S FIVE FORCES ANALYSIS 62
TABLE 4 PORTER’S FIVE FORCES ANALYSIS: METABOLISM ASSAYS MARKET 62
5.8.1 THREAT OF NEW ENTRANTS 62
5.8.2 THREAT OF SUBSTITUTES 62
5.8.3 BARGAINING POWER OF SUPPLIERS 62
5.8.4 BARGAINING POWER OF BUYERS 62
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 63
5.9 REGULATORY ANALYSIS 63
5.9.1 NORTH AMERICA 63
5.9.1.1 US 63
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION 63
5.9.1.2 Canada 64
TABLE 6 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 64
5.9.2 EUROPE 64
5.9.3 ASIA PACIFIC 65
5.9.3.1 Japan 65
TABLE 7 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 65
5.9.3.2 China 65
TABLE 8 CHINA: CLASSIFICATION OF MEDICAL DEVICES 66
5.9.3.3 India 66
5.10 TRADE ANALYSIS 66
TABLE 9 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018–2022 (USD MILLION) 67
TABLE 10 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018–2022 (USD MILLION) 67
5.11 TECHNOLOGY ANALYSIS 68
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 68
TABLE 11 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2023–2024 68
5.13 TRENDS/DISRUPTIONS IMPACTING BUSINESSES 69
5.13.1 REVENUE SHIFT IN METABOLISM ASSAYS 69
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 70
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 70
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS 70
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS 70
5.14.2 BUYING CRITERIA 71
FIGURE 26 KEY BUYING CRITERIA FOR METABOLISM ASSAYS 71
TABLE 13 KEY BUYING CRITERIA FOR METABOLISM ASSAYS 71
6 METABOLISM ASSAYS MARKET, BY PRODUCT 72
6.1 INTRODUCTION 73
TABLE 14 METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 73
6.2 ASSAY KITS & REAGENTS 73
6.2.1 COST-EFFECTIVENESS TO INCREASE ADOPTION IN DRUG DISCOVERY 73
TABLE 15 ASSAY KITS AVAILABLE IN MARKET 74
TABLE 16 METABOLISM ASSAYS MARKET: ASSAY KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 74
6.3 INSTRUMENTS & ANALYZERS 74
6.3.1 AUTOMATION IN INSTRUMENTS, ALONG WITH ADOPTION OF SOFTWARE, TO DRIVE SEGMENTAL GROWTH 74
TABLE 17 INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET 75
TABLE 18 METABOLISM ASSAYS MARKET: INSTRUMENTS & ANALYZERS, BY REGION, 2021–2028 (USD MILLION) 76
7 METABOLISM ASSAYS MARKET, BY TECHNOLOGY 77
7.1 INTRODUCTION 78
TABLE 19 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 78
7.2 COLORIMETRY 78
7.2.1 COST-EFFECTIVENESS TO DRIVE MARKET 78
TABLE 20 METABOLISM ASSAYS MARKET FOR COLORIMETRY, BY REGION, 2021–2028 (USD MILLION) 79
7.3 FLUORIMETRY 79
7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO DRIVE MARKET 79
TABLE 21 METABOLISM ASSAYS MARKET FOR FLUORIMETRY, BY REGION, 2021–2028 (USD MILLION) 80
7.4 SPECTROMETRY 80
7.4.1 INCREASED IMPORTANCE IN RESEARCH AND CLINICAL DIAGNOSTICS TO DRIVE MARKET 80
TABLE 22 METABOLISM ASSAYS MARKET FOR SPECTROMETRY, BY REGION, 2021–2028 (USD MILLION) 81
8 METABOLISM ASSAYS MARKET, BY APPLICATION 82
8.1 INTRODUCTION 83
TABLE 23 METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 83
8.2 DIAGNOSTICS 83
8.2.1 GROWING PREVALENCE OF METABOLIC AND CHRONIC DISEASES TO DRIVE MARKET 83
TABLE 24 DIAGNOSTICS: METABOLISM ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 84
TABLE 25 METABOLISM ASSAYS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 84
8.2.2 DIABETES 84
TABLE 26 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION) 85
8.2.3 OBESITY 85
TABLE 27 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OBESITY, BY REGION, 2021–2028 (USD MILLION) 86
8.2.4 CANCER 86
TABLE 28 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 87
8.2.5 CARDIOVASCULAR DISEASES 87
TABLE 29 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 88
8.2.6 OTHER DIAGNOSTICS 88
TABLE 30 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OTHER DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 89
8.3 RESEARCH 89
8.3.1 INCREASE IN AWARENESS OF METABOLISM ASSAY IN DISEASE RESEARCH 89
TABLE 31 RESEARCH: METABOLISM ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 90
9 METABOLISM ASSAYS MARKET, BY END USER 91
9.1 INTRODUCTION 92
TABLE 32 METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 92
9.2 HOSPITALS 92
9.2.1 AFFORDABILITY AND CONVENIENCE TO DRIVE SEGMENT 92
TABLE 33 METABOLISM ASSAYS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 93
9.3 DIAGNOSTIC LABORATORIES 93
9.3.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET 93
TABLE 34 METABOLISM ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 94
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES 94
9.4.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 94
TABLE 35 METABOLISM ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 95
10 METABOLISM ASSAYS MARKET, BY REGION 96
10.1 INTRODUCTION 97
TABLE 36 METABOLISM ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 97
10.2 NORTH AMERICA 97
FIGURE 27 NORTH AMERICA: METABOLISM ASSAYS MARKET SNAPSHOT 98
TABLE 37 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 38 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99
TABLE 39 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 99
TABLE 40 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 99
TABLE 41 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 100
10.2.1 RECESSION IMPACT 100
10.2.2 US 100
10.2.2.1 High rate of drug discovery and toxicity testing to drive market 100
TABLE 42 US: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 101
TABLE 43 US: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 101
TABLE 44 US: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 102
TABLE 45 US: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 102
10.2.3 CANADA 102
10.2.3.1 High prevalence of obesity to fuel market growth 102
TABLE 46 CANADA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103
TABLE 47 CANADA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 103
TABLE 48 CANADA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 104
TABLE 49 CANADA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 104
10.3 EUROPE 104
TABLE 50 EUROPE: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 51 EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 105
TABLE 52 EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 106
TABLE 53 EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 106
TABLE 54 EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
10.3.1 RECESSION IMPACT 107
10.3.2 GERMANY 107
10.3.2.1 Growth of pharmaceutical companies to drive market 107
TABLE 55 GERMANY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108
TABLE 56 GERMANY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 108
TABLE 57 GERMANY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 109
TABLE 58 GERMANY: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 109
10.3.3 UK 109
10.3.3.1 Growing cancer research funding to drive market 109
TABLE 59 UK: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 110
TABLE 60 UK: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 111
TABLE 61 UK: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 62 UK: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
10.3.4 FRANCE 112
10.3.4.1 Rising obese population and prevalence of metabolic disorders to drive market 112
TABLE 63 FRANCE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 112
TABLE 64 FRANCE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 113
TABLE 65 FRANCE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 113
TABLE 66 FRANCE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
10.3.5 SPAIN 114
10.3.5.1 Increasing prevalence of aging population and diabetes to drive market 114
TABLE 67 SPAIN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 114
TABLE 68 SPAIN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 115
TABLE 69 SPAIN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 70 SPAIN: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 115
10.3.6 ITALY 116
10.3.6.1 Growth of pharmaceutical industry to boost market 116
TABLE 71 ITALY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 116
TABLE 72 ITALY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 117
TABLE 73 ITALY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 117
TABLE 74 ITALY: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 117
10.3.7 REST OF EUROPE 118
TABLE 75 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 118
TABLE 76 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 119
TABLE 77 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 78 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 120
10.4 ASIA PACIFIC 121
FIGURE 28 ASIA PACIFIC: METABOLISM ASSAYS MARKET SNAPSHOT 121
10.4.1 RECESSION IMPACT 122
TABLE 79 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 80 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 81 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123
TABLE 82 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 123
TABLE 83 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 124
10.4.2 JAPAN 124
10.4.2.1 Government initiatives to drive market 124
TABLE 84 JAPAN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 85 JAPAN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 125
TABLE 86 JAPAN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 87 JAPAN: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 126
10.4.3 CHINA 126
10.4.3.1 Increasing health awareness to drive demand 126
TABLE 88 CHINA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127
TABLE 89 CHINA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
TABLE 90 CHINA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 91 CHINA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10.4.4 INDIA 129
10.4.4.1 Prevalence of chronic diseases to fuel demand 129
TABLE 92 INDIA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 130
TABLE 93 INDIA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 130
TABLE 94 INDIA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131
TABLE 95 INDIA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 131
10.4.5 REST OF ASIA PACIFIC 131
TABLE 96 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 132
TABLE 97 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
TABLE 98 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 133
TABLE 99 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 134
10.5 REST OF THE WORLD 134
10.5.1 RECESSION IMPACT 135
TABLE 100 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 135
TABLE 101 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 136
TABLE 102 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 103 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION) 137
11 COMPETITIVE LANDSCAPE 138
11.1 OVERVIEW 138
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 138
TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES 138
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 139
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN METABOLISM ASSAYS MARKET 139
11.4 MARKET RANKING ANALYSIS 140
FIGURE 30 METABOLISM ASSAYS MARKET RANKING ANALYSIS, BY KEY PLAYER (2022) 140
11.5 COMPANY EVALUATION QUADRANT (2022) 140
11.5.1 STARS 140
11.5.2 EMERGING LEADERS 140
11.5.3 PERVASIVE PLAYERS 141
11.5.4 PARTICIPANTS 141
FIGURE 31 METABOLISM ASSAYS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022 141
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022) 142
11.6.1 PROGRESSIVE COMPANIES 142
11.6.2 STARTING BLOCKS 142
11.6.3 RESPONSIVE COMPANIES 142
11.6.4 DYNAMIC COMPANIES 142
FIGURE 32 METABOLISM ASSAY MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022 143
11.7 COMPETITIVE BENCHMARKING 144
TABLE 105 METABOLISM ASSAYS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 144
TABLE 106 PRODUCT FOOTPRINT OF KEY PLAYERS 145
TABLE 107 REGIONAL FOOTPRINT OF KEY PLAYERS 146
TABLE 108 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 147
11.8 COMPETITIVE SCENARIO 147
11.8.1 PRODUCT LAUNCHES 147
TABLE 109 PRODUCT LAUNCHES, JANUARY 2020–AUGUST 2023 147
11.8.2 DEALS 148
TABLE 110 DEALS, JANUARY 2020–AUGUST 2023 148
11.8.3 OTHER DEVELOPMENTS 148
TABLE 111 OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2023 148
12 COMPANY PROFILES 149
12.1 KEY PLAYERS 149
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 THERMO FISHER SCIENTIFIC INC. 149
TABLE 112 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 149
FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 150
12.1.2 MERCK KGAA 153
TABLE 113 MERCK KGAA: BUSINESS OVERVIEW 153
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022) 154
12.1.3 ABCAM PLC. 156
TABLE 114 ABCAM PLC.: BUSINESS OVERVIEW 156
FIGURE 35 ABCAM PLC.: COMPANY SNAPSHOT (2022) 157
TABLE 115 ABCAM PLC.: DEALS 159
12.1.4 AGILENT TECHNOLOGIES INC. 160
TABLE 116 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW 160
FIGURE 36 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022) 161
TABLE 117 AGILENT TECHNOLOGIES INC.: PRODUCT LAUNCHES 162
12.1.5 KANEKA EUROGENTEC S.A. 163
TABLE 118 KANEKA EUROGENTEC S.A.: BUSINESS OVERVIEW 163
FIGURE 37 KANEKA EUROGENTEC S.A.: COMPANY SNAPSHOT (2022) 163
12.1.6 SARTORIUS AG 166
TABLE 119 SARTORIUS AG: BUSINESS OVERVIEW 166
FIGURE 38 SARTORIUS AG: COMPANY SNAPSHOT (2022) 166
TABLE 120 SARTORIUS AG: PRODUCT LAUNCHES 167
12.1.7 PROMEGA CORPORATION 168
TABLE 121 PROMEGA CORPORATION: BUSINESS OVERVIEW 168
12.1.8 ELABSCIENCE BIOTECHNOLOGY INC. 169
TABLE 122 ELABSCIENCE BIOTECHNOLOGY INC.: BUSINESS OVERVIEW 169
12.1.9 RAYBIOTECH LIFE, INC. 172
TABLE 123 RAYBIOTECH LIFE, INC.: BUSINESS OVERVIEW 172
12.1.10 BMG LABTECH 173
TABLE 124 BMG LABTECH: BUSINESS OVERVIEW 173
TABLE 125 BMG LABTECH: PRODUCT LAUNCHES 173
12.1.11 BIOTREND CHEMIKALIEN GMBH 174
TABLE 126 BIOTREND CHEMIKALIEN GMBH: BUSINESS OVERVIEW 174
12.2 OTHER PLAYERS 175
12.2.1 3H BIOMEDICAL AB 175
12.2.2 BIOASSAY SYSTEMS 176
12.2.3 EMELCA BIOSCIENCE 177
12.2.4 CREATIVE BIOARRAY 178
12.2.5 TEMPO BIOSCIENCE, INC. 179
12.2.6 NCARDIA 180
12.2.7 NOVOCIB 181
12.2.8 ETON BIOSCIENCE, INC. 182
12.2.9 CAYMAN CHEMICAL COMPANY 182
12.2.10 ENZO LIFE SCIENCES, INC. 183
12.2.11 ABNOVA CORPORATION 184
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 185
13.1 DISCUSSION GUIDE 185
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 189
13.3 CUSTOMIZATION OPTIONS 191
13.4 RELATED REPORTS 191
13.5 AUTHOR DETAILS 192